Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Model

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. WBD
3. NVDA
4. USO
5. PSKY
6. TSLA
7. AMD
8. META
9. AMC
10. NUAI

Go back to Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Model
(NASDAQ: PPCB) Delayed: 0.64 +0.03 (4.92%)
Previous Close $0.61    52 Week High $ 
Open $0.61    52 Week Low $ 
Day High $0.65    P/E N/A 
Day Low $0.60    EPS $ 
Volume 126,084